Enlivex Therapeutics announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for patent application number 16/076,026. Once issued, the resulting patent will provide Enlivex with added intellectual property protection through at least 2036 with claims covering methods of using Allocetra in combination with chimeric antigen receptor, CAR, T-cell therapy to treat, ameliorate or allveiate tumors. The Company expects that this new patent will be issued in the United States during 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ENLV:
- Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy
- Enlivex Therapeutics appoints Singer to its board of directors
- Enlivex Appoints Andrew Singer to its Board of Directors
- Enlivex, BeiGene enter clinical collaboration agreement
- Enlivex Therapeutics provides business updates on clinical programs
